Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mayo Clinic and SV Bio Enter Strategic Relationship on Genome Diagnostics and Interpretation

Published: Thursday, January 24, 2013
Last Updated: Thursday, January 24, 2013
Bookmark and Share
SV Bio’s turnkey solutions to support newly launched Individualized Medicine Clinic.

Mayo Clinic and Silicon Valley Biosystems (SV Bio) today announced a strategic collaboration for whole genome diagnostics and interpretation at the Mayo Clinic Center for Individualized Medicine and at Mayo Medical Laboratories. This strategic collaboration unites SV Bio’s proprietary genome interpretation solution with Mayo Clinic’s growing genome reference library and its commitment to individualized medicine, and will increase accessibility and clinical utility of next-generation sequencing for patients. SV Bio will provide clinical genome interpretation services and clinical decision support interfaces to Mayo Clinic, and Mayo’s Center for Individualized Medicine will contribute clinical and laboratory expertise and support. Financial details of the agreement were not disclosed.

“At Mayo Clinic, we are committed to integrating genomic medicine into the continuum of care for all of our patients,” says Gianrico Farrugia, M.D., director of the Mayo Clinic Center for Individualized Medicine. “The Individualized Medicine Clinic represents one of Mayo’s bold steps toward realizing the promise of these game-changing technologies and toward offering new hope to patients, including those with cancer and diagnostic dilemmas.”

While the rapidly declining cost of sequencing has been widely heralded and has led to varying degrees of clinical implementation at a handful of health care organizations, managing the sheer volume of data remains a bottleneck to widespread application of personalized medicine.

“Every human disease has a genetic component but, to date, medical providers have not been able to fully utilize this information to improve clinical outcomes,” says Dietrich Stephan, Ph.D., founder, president and CEO of SV Bio. “With the SV Bio platform, we’ve made the translation to a single assay — a full human genome — with the diagnostics rapidly and precisely happening in silico.” The SV Bio process is fully computerized and automated and reduces the time needed for clinically actionable genome interpretation from several weeks to a few minutes and puts the results in the provider’s hands at the point of care.

The goal of the collaboration is to unlock the full potential of next-generation sequencing and open these technologies to every patient. SV Bio’s turnkey genomics interpretation solutions query a patient’s genome at the point of care and distill the biological data into a concise, actionable report that physicians can use to make faster, more informed decisions. Mayo Clinic will provide medical and scientific expertise to help ensure patients receive the maximum benefit.

“We are now able to take data from any next-generation sequencer and determine with clinical grade sensitivity and specificity which variants within a patient’s DNA sequence are influencing a disease or condition, and rapidly provide a report for the clinician that is clear and actionable,” Dr. Stephan says. “This level of speed, accuracy and integration into the clinical work flow is not only a first for molecular testing, but also a sea change in the application of next-generation sequencing with no compromise of quality in clinical diagnostics.”

As part of the collaboration, Mayo Medical Laboratories, the reference laboratory that provides services worldwide, and SV Bio will work together to refine approaches to clinical genome interpretation.

“In our laboratories, we are rapidly adopting and implementing next-generation sequencing as a platform upon which we will be providing cutting-edge genome-based testing,” says Franklin Cockerill, M.D., president of Mayo Medical Laboratories. “This collaboration with SV Bio furthers our mission of bringing the latest diagnostic technologies to health care providers around the world.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Rescuing Genetic Material from Formaldehyde Treated Tissue Samples
Formaldehyde is excellent for preserving cellular structures, but it makes it difficult to pull genetic information from tissue samples. Eric Kool and colleagues have developed a catalyst that saves RNA, which could lead to better patient outcomes.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
Web App Helps Researchers Explore Cancer Genetics
Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.
New Research Advances Genetic Studies in Wildlife Conservation
‘Next-gen’ DNA sequencing of non-invasively collected hair expands field of conservation genetics.
Gene Testing Now Allows Precision Medicine for Thoracic Aneurysms
Researchers at the Aortic Institute at Yale have tested the genomes of more than 100 patients with thoracic aortic aneurysms, a potentially lethal condition, and provided genetically personalized care.
OGT’s Popular ESHG Workshop Free to View Online
Learn about the next generation of microarrays in one of the best attended workshops of the conference.
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Sperm RNA Test May Improve Evaluation of Male Infertility
To help resolve uncertainty—and guide prospective parents to the right fertility treatments—scientists propose the use of a new kind of fertility test. It involves examining sperm RNA by means of next-generation sequencing.
How the Mammoth Got its Wool
Evolutionary change in a gene reconstructed in the lab from the woolly mammoth was part of a suite of adaptations that allowed the mammoth to survive in harsh arctic environments, according to new research.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!